Taiwan Stock Exchange · Healthcare
Formosa Laboratories stock from India: price, numbers and tax
Formosa Laboratories (4746) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Formosa Laboratories at a glance
- Price
- NT$49.00+NT$0.05 (0.10%)
- Market cap
- NT$5.89B
- Day range
- NT$48.60 – NT$49.30
- P/E
- 12.34
- Dividend yield
- 6.12%
- Volume
- 444.26K
- 1 month
- +0.51%
- 6 months
- -12.50%
- YTD
- -17.37%
- 1 year
- -26.20%
- 5 years
- -18.74%
Formosa Laboratories statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$4.9B | NT$4.7B | NT$4.4B | NT$3.8B | NT$3.1B |
| Gross profit | NT$2.0B | NT$2.0B | NT$1.9B | NT$1.4B | NT$971.4M |
| Operating income | NT$803.2M | NT$750.0M | NT$675.0M | NT$380.8M | NT$1.1B |
| Net income | NT$441.1M | NT$157.3M | NT$126.2M | NT$216.8M | NT$1.2B |
| Earnings per share | NT$3.67 | NT$1.31 | NT$1.05 | NT$1.80 | NT$10.92 |
| EBITDA | NT$1.4B | NT$746.9M | NT$1.2B | NT$823.4M | NT$1.6B |
| Total assets | NT$13.8B | NT$13.9B | NT$13.6B | NT$12.8B | NT$12.0B |
| Total debt | NT$3.6B | NT$3.9B | NT$4.1B | NT$3.8B | NT$3.4B |
| Cash and short-term investments | NT$2.5B | NT$2.7B | NT$2.5B | NT$1.6B | NT$1.1B |
| Shareholders' equity | NT$7.8B | NT$7.7B | NT$7.6B | NT$7.5B | NT$7.4B |
| Operating cash flow | NT$1.3B | NT$726.3M | NT$826.6M | NT$643.1M | NT$311.2M |
| Free cash flow | NT$472.1M | NT$138.5M | NT$286.1M | NT$203.1M | −NT$202.7M |
| Capital expenditure | −NT$843.1M | −NT$587.9M | −NT$540.5M | −NT$440.0M | −NT$513.8M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| CHO Pharma | 6586.TWO | $117.00 | $25.04B |
| Standard Chem & Pharm | 1720.TW | NT$56.10 | NT$11.03B |
| Adimmune | 4142.TW | NT$18.10 | NT$7.63B |
| SCI Pharmtech | 4119.TW | NT$55.70 | NT$6.66B |
| TaiGen Biopharmaceuticals | 4157.TWO | $8.73 | $6.21B |
| Orient Pharma | 4166.TWO | $24.75 | $6.02B |
| Delta Asia International | 6762.TWO | $156.00 | $5.76B |
| Mycenax Biotech | 4726.TWO | $23.40 | $4.84B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Formosa Laboratories from India
What Formosa Laboratories does
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in… Formosa Laboratories operates in the Medical - Pharmaceuticals industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Formosa Laboratories shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.